Intervacc (IVACC.ST) Stock Analysis & AI Equity Report
Intervacc (IVACC.ST) overview
Intervacc (IVACC.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Intervacc reported revenue of SEK 11.8m and operating profit of SEK -77.3m; the year-end share price was 1.00 SEK and market capitalisation was SEK 88.3m. Intervacc is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Intervacc's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Intervacc
Intervacc AB is a Swedish biotechnology company focused on animal health. It develops veterinary vaccines based on recombinant proteins, with Strangvac as its main product against equine strangles. Through its subsidiary Nordvacc, the group markets veterinary vaccines and animal health products, while Mybac-Vettech provides accredited bacteriological and mycological diagnostic services in Sweden.
Generate the Intervacc report
Intervacc is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Intervacc and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.